WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon... Read More

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7 th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7... Read More

HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 20f24, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy... Read More

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio... Read More

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the c adisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes.... Read More

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over 500 subjects to date, including 300 patients with diabetes HIGH POINT, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical... Read More

WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Cantex's azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be... Read More

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. “The first quarter of 2024 saw us reach several... Read More

Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diagnosed glioblastoma WESTON, Fla. , March 19, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening... Read More

Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the treatment of type 1 diabetes, expected to initiate patient enrollment in the second quarter of 2024. In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members.... Read More

HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the submission of the study protocol to the FDA for the Company’s first Phase 3 trial evaluating the safety and efficacy of its lead candidate,... Read More

HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company management will be presenting at the TD Cowen 44 th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA. The... Read More

HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has closed a private placement to healthcare-focused institutional investors (“the investors”), including a life sciences-focused... Read More

WESTON, Fla. , Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus , M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New... Read More

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “Our newly appointed... Read More

HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will... Read More

HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. “I am pleased to welcome Dr. Strack to the vTv team,”... Read More

HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its... Read More

WESTON, Fla. and ANN ARBOR, Mich. , Sept. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the... Read More

Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options to Pancreatic Cancer Patients WESTON, Fla. and PITTSBURGH , Sept. 26, 2023 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, and Allegheny Health... Read More

Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatment of Newly Diagnosed Unmethylated Glioblastoma WESTON, Fla. and NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, and... Read More

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the first half of... Read More

Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor for advanced glycation end products (RAGE) Researchers showed RAGE inhibition to be a potential target for treatment of triple-negative breast cancer suppressing tumor progression and metastasis WESTON, Fla. , Aug. 10, 2023 /PRNewswire/ -- Cantex Pharmaceuticals , Inc. , a clinical-stage pharmaceutical company focused on developing... Read More

HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin ( TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that Cantex Pharmaceuticals, Inc. recently obtained an exclusive worldwide license from Georgetown University for intellectual property related... Read More

WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc . , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023 , in Boston, MA. Stephen G. Marcus , M.D. Cantex's... Read More

HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that the United States Patent and Trademark Office recently issued a patent to Cantex Pharmaceuticals, Inc. that covers claims related to the use of azeliragon as a... Read More

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first several months of 2023, we... Read More

WESTON, Fla. and ANN ARBOR, Mich. , April 20, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the initiation of a randomized double-blind,... Read More

Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer Biotech industry veteran Elizabeth Keiley appointed Executive Vice President and General Counsel HIGH POINT, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.... Read More

WESTON, Fla. , March 6, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Baptist Health Miami Cancer Institute, part of Baptist Health Cancer Care, the largest cancer program in South Florida , announced today that the U.S. Food and Drug Administration (FDA) has issued a... Read More

Cantex is developing azeliragon as a once-a-day pill for the treatment of glioblastoma and other cancers WESTON, Fla. , Feb. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) reviewed Cantex's Investigational New... Read More

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately. “We welcome Betzy to vTv. Her years of legal expertise and deep experience... Read More

WESTON, Fla. , Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for... Read More

Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials. Entered into agreements with G42 Investments to purchase $25 million in stock, collaborate on clinical trials and exclusively license rights to develop and... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the company as President and Chief Executive Officer, effective August 1, 2022. Rich Nelson, who has been serving as Interim Chief Executive Officer since March 2, 2022, will continue to support the company as... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that the results from the JDRF-supported mechanistic study assessing effects of TTP399 on ketones during acute insulin withdrawal were published in the Diabetes Obesity and Metabolism journal and presented at The American Diabetes... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31,... Read More

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporate Strategic Focus. We are prioritizing the development of our lead program TTP399 , a novel, oral liver selective glucokinase activator, as a potential treatment for patients with type 1 diabetes (“T1D”), as... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021 , and provided an update on the progress of its clinical programs. "I am dedicated to the long-term growth and development of the Company and look forward to working with vTv's talented employees, scientists, and partners during this exciting time," Mr. Nelson said. "The positive Phase 2 study results... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive Officer. Mr. Nelson joined the vTv Board of Directors in 2020, and currently serves as Executive Vice President Corporate & Business Development of Vericast, and Executive Vice... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Key Takeaways include:... Read More

Workforce reduction of 65% Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes, today announced the prioritization of its lead program TTP399 as it gears up for Phase 3 pivotal... Read More

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs. “We plan to refocus vTv’s strategy on TTP399. TTP399 is unique and the most important product in our portfolio with strong equity value potential to our shareholders”, said Deepa Prasad, president and CEO, vTv Therapeutics. “Biotech is about... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and Chief Executive Officer, effective immediately. Stephen L. Holcombe who previously served as vTv's President and Chief Executive Officer will be retiring. Deepa joins vTv as it... Read More

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials expected to begin in early 2022 vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally... Read More

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis. Successful pre-IND meeting with U.S. Food and Drug Administration Division of Dermatology and Dentistry supports planned IND submission for a Phase 2 study in moderate to... Read More

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs. “We held our first, highly-productive meeting with the FDA following the designation of Breakthrough Therapy for TTP399 as a potential adjunct treatment for type 1 diabetes,” said Steve Holcombe, president and CEO, vTv Therapeutics. “Based upon the... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6 th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in... Read More

vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts). Stephen Marcus, M.D., president and chief executive officer of Cantex, stated: “RAGE has been... Read More

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of HPP737 vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2021, and provided an update on the progress of its clinical programs. “The vTv team continued to build on the clinical... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. TTP399 is a novel, oral, investigational once-daily... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported SimpliciT-1 Study will be presented at A Scientific Symposium: In celebration of the 100th anniversary of the University of Toronto’s discovery of insulin (Insulin100) held virtually,... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using TTP399, the company’s oral glucokinase activator. The patent number is 10,952,993 (‘993 Patent). The ‘993 Patent, expiring in 2039, includes claims covering a method of lowering HbA1c and also reducing the incidence of hypoglycemia in patients with type 1... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. The phase 1 study will test the hypothesis that treatment... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C. Wainwright Global Life Sciences Conference held virtually March 9-10, 2021. The company will be providing a general company update through a virtual presentation that will be available on demand... Read More

Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2020, and provided an update on the progress of its clinical... Read More

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) and inflammatory diseases, today announced that the results from the JDRF-supported SimpliciT-1 Study were published in the American Diabetes Association’s Diabetes Care journal. The SimpliciT-1 Study was a multi-center, randomized, double-blind, adaptive... Read More

Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara Biopharma, has initiated a phase 2 study in COPD in China vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and... Read More